NTT DATA Named a Leader in IDC MarketScape for Worldwide Cloud Professional Services
10.7.2024 15:00:00 EEST | Business Wire | Press release
NTT DATA, a global digital business and IT services leader, today announced it has been named a Leader in the IDC MarketScape: Worldwide Cloud Professional Services 2024 Vendor Assessment report (Doc #US51406224, June 2024)
The report evaluated 24 cloud professional services providers on key measures of success across two primary categories: capabilities and strategies. IDC recognized NTT DATA for the evolution of its cloud professional services over the last two years, citing its integrated capabilities to create a broader portfolio of IT and connectivity services, wider industry-focused consulting, and more global scale.
IDC recognized NTT DATA for its broad range of digital offerings includes business consulting, data & intelligence, customer experience & design, network and application services, cybersecurity, and cloud and IT infrastructure. The report noted the evolution of NTT DATA’s cloud professional services as a particular strength, as it expanded not only the breadth of its offering, but also its tooling and methods. The company's other strengths include sales and distribution, as well as its customer retention strategies.
"A strength of NTT DATA is the evolution of its cloud professional services over the past two years, expanding not only its offering breadth but also its tooling and methods," said Gard Little, Research Vice President, IDC. "Clients noted NTT DATA's high level of technical capabilities for cloud modernization and migration, as well as for agile development. Likewise, clients have appreciated the results NTT DATA can deliver related to the automation of operational areas such as application releases."
The IDC MarketScape cited cloud clients should consider choosing NTT DATA when seeking “a service provider whose focus is on trust and long-term client relationships.” The report notes that while NTT DATA employs a strategy to deliver greater value based on regional needs, its hybrid culture, and differentiation, is based on its Japanese roots. It also highlighted that NTT DATA’s focus on sustainability and social responsibility is deeply embedded in its corporate DNA, going back to its founding in 1988.
“At NTT DATA, we believe a seamless cloud journey starts with flexibility. Our NTT DATA unified Cloud Adoption Framework (NuCAF) integrates with all major hyperscalers, ensuring a smooth migration and transformation for our clients,” said Hidehiko Tanaka, Head of Technology and Innovation General Headquarters of NTT DATA. “We're doubling down on this commitment by making strategic acquisitions and investments in cutting-edge technologies like generative AI, All-Photonics Network, and smart robotics, alongside key partnerships to propel our clients forward in a sustainable and secure digital future."
According to the report, clients noted “NTT DATA’s high level of technical capabilities for cloud modernization and migration, as well as for agile development.” Clients also appreciate the results NTT DATA can deliver with regard to the automation of operational areas such as application releases.
“We are honored to be recognized as a Leader in the IDC MarketScape for Worldwide Cloud Professional Services,” said Charlie Li, Global Head of Cloud and Security Services of NTT DATA. “This acknowledgement underscores our commitment to delivering business value through a cohesive, full-stack modern portfolio. Over the past two years, we’ve enhanced our AI powered offerings and methodologies tailored to industry needs. IDC’s recognition highlights our strengths in client trust, expertise, and comprehensive cloud capabilities. We remain focused on leveraging our global scale and platform delivered services to drive innovation and exceptional customer experiences.”
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure, and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com.
About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709459471/en/
Contacts
Global Marketing & Communications Headquarters
NTT DATA Group Corporation
global-marketing@kits.nttdata.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom